MedTrace Logo

Molecular Profiling in Prostate Cancer

NCT04983628 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-03-01

No results posted yet for this study

Summary

We aim to employ targeted DNA NGS to evaluate the prevalence of germline and somatic mutations in cancer predisposing genes, such as BRCA1 and BRCA2, and other HR and DDR genes, including also a few additional clinically relevant genes, in patients with metastatic, locally advanced or high-grade prostate cancer. In addition, we will investigate the prognostic role of these mutations as well as their association with various clinicopathological parameters. This will be the first study investigating the prevalence of germline and somatic pathogenic mutations in Greek patients with prostate cancer.

Conditions

  • Prostate Cancer Metastatic
  • Prostate Cancer Recurrent
  • Germline BRCA1 Gene Mutation
  • Germline BRCA2 Gene Mutation
  • Mutation

Interventions

OTHER

Tumor molecular profiling

targeted DNA NGS

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Elena Fountzila · HeCOG

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2023-01-30
Completion
2023-08-01

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04983628 on ClinicalTrials.gov